BJMO - volume 10, issue 7, november 2016
T. Vermassen PhD, A. De Meulenaere MD, M. Van de Walle MD, S. Rottey MD, PhD
Summary
Renal cell carcinoma accounts for 2.4% of all malignancies worldwide diagnosed with 338,000 estimated new cases globally in 2012. In the last decade, the therapeutic landscape for renal cell carcinoma patients has changed tremendously. In this review, we will summarise the treatment options currently available for clear-cell localised, advanced and metastatic renal cell carcinoma; as stated in the ESMO clinical practice guidelines, the EAU guidelines and the NCCN guidelines. Furthermore we will discuss the recommended therapies in patients diagnosed with non-clear cell tumours.
(BELG J MED ONCOL 2016;10(7):256–262)
Read more
Top
